Show simple item record

dc.contributor.authorEscudier, B
dc.contributor.authorPorta, C
dc.contributor.authorBono, P
dc.contributor.authorPowles, T
dc.contributor.authorEisen, T
dc.contributor.authorSternberg, C
dc.contributor.authorGschwend, J
dc.contributor.authorDe Giorgi, U
dc.contributor.authorParikh, O
dc.contributor.authorHawkins, Robert E
dc.contributor.authorSevin, E
dc.contributor.authorNégrier, Sy
dc.contributor.authorKhan, S
dc.contributor.authorDiaz, J
dc.contributor.authorRedhu, S
dc.contributor.authorMehmud, F
dc.contributor.authorCella, D
dc.date.accessioned2014-04-17T14:32:22Z
dc.date.available2014-04-17T14:32:22Z
dc.date.issued2014-03-31
dc.identifier.citationRandomized, controlled, double-blind, cross-over trial assessing treatment preference for Pazopanib versus Sunitinib in patients with metastatic renal cell carcinoma: PISCES study. 2014: J Clin Oncolen
dc.identifier.issn1527-7755
dc.identifier.pmid24687826
dc.identifier.doi10.1200/JCO.2013.50.8267
dc.identifier.urihttp://hdl.handle.net/10541/315948
dc.description.abstractPatient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy. This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen
dc.titleRandomized, controlled, double-blind, cross-over trial assessing treatment preference for Pazopanib versus Sunitinib in patients with metastatic renal cell carcinoma: PISCES study.en
dc.typeArticleen
dc.contributor.departmentBernard Escudier, Institut Gustave Roussy, Villejuifen
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPatient-reported outcomes may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly between approved targeted therapies with similar efficacy. This double-blind cross-over study evaluated patient preference for pazopanib or sunitinib and the influence of health-related quality of life (HRQoL) and safety factors on their stated preference.


This item appears in the following Collection(s)

Show simple item record